300 related articles for article (PubMed ID: 30848558)
1. A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis.
Deodhar A; Gensler LS; Kay J; Maksymowych WP; Haroon N; Landewé R; Rudwaleit M; Hall S; Bauer L; Hoepken B; de Peyrecave N; Kilgallen B; van der Heijde D
Arthritis Rheumatol; 2019 Jul; 71(7):1101-1111. PubMed ID: 30848558
[TBL] [Abstract][Full Text] [Related]
2. Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol.
Maksymowych WP; Kumke T; Auteri SE; Hoepken B; Bauer L; Rudwaleit M
Arthritis Res Ther; 2021 Oct; 23(1):274. PubMed ID: 34715908
[TBL] [Abstract][Full Text] [Related]
3. Impact of Certolizumab Pegol on Patient-Reported Outcomes in Patients With Axial Spondyloarthritis.
Sieper J; Kivitz A; van Tubergen A; Deodhar A; Coteur G; Woltering F; Landewé R
Arthritis Care Res (Hoboken); 2015 Oct; 67(10):1475-80. PubMed ID: 25832312
[TBL] [Abstract][Full Text] [Related]
4. Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis.
Rudwaleit M; Rosenbaum JT; Landewé R; Marzo-Ortega H; Sieper J; van der Heijde D; Davies O; Bartz H; Hoepken B; Nurminen T; Deodhar A
Arthritis Care Res (Hoboken); 2016 Jun; 68(6):838-44. PubMed ID: 26815944
[TBL] [Abstract][Full Text] [Related]
5. Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial.
Sieper J; Landewé R; Rudwaleit M; van der Heijde D; Dougados M; Mease PJ; Braun J; Deodhar A; Kivitz A; Walsh J; Hoepken B; Nurminen T; Maksymowych WP
Arthritis Rheumatol; 2015 Mar; 67(3):668-77. PubMed ID: 25470228
[TBL] [Abstract][Full Text] [Related]
6. Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction.
Landewé RB; van der Heijde D; Dougados M; Baraliakos X; Van den Bosch FE; Gaffney K; Bauer L; Hoepken B; Davies OR; de Peyrecave N; Thomas K; Gensler LS
Ann Rheum Dis; 2020 Jul; 79(7):920-928. PubMed ID: 32381562
[TBL] [Abstract][Full Text] [Related]
7. Brief Report: Clinical Course Over Two Years in Patients With Early Nonradiographic Axial Spondyloarthritis and Patients With Ankylosing Spondylitis Not Treated With Tumor Necrosis Factor Blockers: Results From the German Spondyloarthritis Inception Cohort.
Poddubnyy D; Haibel H; Braun J; Rudwaleit M; Sieper J
Arthritis Rheumatol; 2015 Sep; 67(9):2369-75. PubMed ID: 26017497
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study.
van der Heijde D; Gensler LS; Maksymowych WP; Landewé R; Rudwaleit M; Bauer L; Kumke T; Kim M; Auteri SE; Hoepken B; Deodhar A
RMD Open; 2022 Mar; 8(1):. PubMed ID: 35296532
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis.
Sieper J; van der Heijde D; Dougados M; Maksymowych WP; Scott BB; Boice JA; Berd Y; Bergman G; Curtis S; Tzontcheva A; Huyck S; Weng HH
Arthritis Rheumatol; 2015 Oct; 67(10):2702-12. PubMed ID: 26139307
[TBL] [Abstract][Full Text] [Related]
10. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial.
Dougados M; van der Heijde D; Sieper J; Braun J; Maksymowych WP; Citera G; Miceli-Richard C; Wei JC; Pedersen R; Bonin R; Rahman MU; Logeart I; Wajdula J; Koenig AS; Vlahos B; Alvarez D; Bukowski JF
Arthritis Rheumatol; 2014 Aug; 66(8):2091-102. PubMed ID: 24891317
[TBL] [Abstract][Full Text] [Related]
11. Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104-Week Results From a Randomized, Placebo-Controlled Study.
Dougados M; van der Heijde D; Sieper J; Braun J; Citera G; Lenaerts J; van den Bosch F; Wei JC; Pedersen R; Bonin R; Jones H; Marshall L; Logeart I; Vlahos B; Bukowski JF; Maksymowych WP
Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1590-1598. PubMed ID: 28482137
[TBL] [Abstract][Full Text] [Related]
12. Is Treatment in Patients With Suspected Nonradiographic Axial Spondyloarthritis Effective? Six-Month Results of a Placebo-Controlled Trial.
Rusman T; van der Weijden MAC; Nurmohamed MT; Landewé RBM; de Winter JJH; Boden BJH; Bet PM; van der Bijl CMA; van der Laken C; van der Horst-Bruinsma IE
Arthritis Rheumatol; 2021 May; 73(5):806-815. PubMed ID: 33277982
[TBL] [Abstract][Full Text] [Related]
13. Rapid onset of efficacy predicts response to therapy with certolizumab plus methotrexate in patients with active rheumatoid arthritis.
Kang YM; Park YE; Park W; Choe JY; Cho CS; Shim SC; Bae SC; Suh CH; Cha HS; Koh EM; Song YW; Yoo B; Lee SS; Park MC; Lee SH; Arendt C; Koetse W; Lee SK
Korean J Intern Med; 2018 Nov; 33(6):1224-1233. PubMed ID: 29294598
[TBL] [Abstract][Full Text] [Related]
14. Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status.
Rudwaleit M; Deodhar A; Bauer L; Gensler L; Hoepken B; Kumke T; Auteri SE; Kim M; Maksymowych W
RMD Open; 2024 May; 10(2):. PubMed ID: 38724259
[TBL] [Abstract][Full Text] [Related]
15. Progression of Structural Damage in the Sacroiliac Joints in Patients With Early Axial Spondyloarthritis During Long-Term Anti-Tumor Necrosis Factor Treatment: Six-Year Results of Continuous Treatment With Etanercept.
Rios Rodriguez V; Hermann KG; Weiß A; Listing J; Haibel H; Althoff C; Proft F; Behmer O; Sieper J; Poddubnyy D
Arthritis Rheumatol; 2019 May; 71(5):722-728. PubMed ID: 30625261
[TBL] [Abstract][Full Text] [Related]
16. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
Weinblatt ME; Fleischmann R; van Vollenhoven RF; Emery P; Huizinga TW; Cutolo M; van der Heijde D; Duncan B; Davies O; Luijtens K; Dougados M
Arthritis Res Ther; 2015 Nov; 17():325. PubMed ID: 26568428
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.
Deodhar A; Poddubnyy D; Pacheco-Tena C; Salvarani C; Lespessailles E; Rahman P; Järvinen P; Sanchez-Burson J; Gaffney K; Lee EB; Krishnan E; Santisteban S; Li X; Zhao F; Carlier H; Reveille JD;
Arthritis Rheumatol; 2019 Apr; 71(4):599-611. PubMed ID: 30343531
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.
Glatt S; Taylor PC; McInnes IB; Schett G; Landewé R; Baeten D; Ionescu L; Strimenopoulou F; Watling MIL; Shaw S
Ann Rheum Dis; 2019 Aug; 78(8):1033-1040. PubMed ID: 31177099
[TBL] [Abstract][Full Text] [Related]
19. Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis.
van der Heijde D; Deodhar A; Fleischmann R; Mease PJ; Rudwaleit M; Nurminen T; Davies O
Arthritis Care Res (Hoboken); 2017 Jul; 69(7):1030-1039. PubMed ID: 27696727
[TBL] [Abstract][Full Text] [Related]
20. The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW.
van der Horst-Bruinsma I; van Bentum R; Verbraak FD; Rath T; Rosenbaum JT; Misterska-Skora M; Hoepken B; Irvin-Sellers O; VanLunen B; Bauer L; Rudwaleit M
RMD Open; 2020 Apr; 6(1):. PubMed ID: 32371433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
